Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.

ABSTRACT:

Background

The total population health benefits and costs of HIV preexposure prophylaxis (PrEP) for people who inject drugs (PWID) in the United States are unclear.

Objective

To evaluate the cost-effectiveness and optimal delivery conditions of PrEP for PWID.

Design

Empirically calibrated dynamic compartmental model.

Data sources

Published literature and expert opinion.

Target population

Adult U.S. PWID.

Time horizon

20 years and lifetime.

Intervention

PrEP alone, PrEP with frequent screening (PrEP+screen), and PrEP+screen with enhanced provision of antiretroviral therapy (ART) for individuals who become infected (PrEP+screen+ART). All scenarios are considered at 25% coverage.

Outcome measures

Infections averted, deaths averted, chan

SUBMITTER: Bernard CL 

PROVIDER: S-EPMC5118181 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature